113 related articles for article (PubMed ID: 14601101)
1. Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy.
Brostjan C; Bayer A; Zommer A; Gornikiewicz A; Roka S; Benkö T; Yaghubian R; Jakesz R; Steger G; Gnant M; Friedl J; Stift A
Cancer; 2003 Nov; 98(10):2291-301. PubMed ID: 14601101
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic active immunotherapy: a new approach to cancer treatment.
Pan J; Jin P; Yan J; Kabelitz D
Cancer Immunol Immunother; 2008 Aug; 57(8):1105-14. PubMed ID: 18214475
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
Bremnes RM; Camps C; Sirera R
Lung Cancer; 2006 Feb; 51(2):143-58. PubMed ID: 16360975
[TBL] [Abstract][Full Text] [Related]
4. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells.
Rabascio C; Muratori E; Mancuso P; Calleri A; Raia V; Foutz T; Cinieri S; Veronesi G; Pruneri G; Lampertico P; Iavarone M; Martinelli G; Goldhirsch A; Bertolini F
Cancer Res; 2004 Jun; 64(12):4373-7. PubMed ID: 15205354
[TBL] [Abstract][Full Text] [Related]
5. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
Loveland BE; Zhao A; White S; Gan H; Hamilton K; Xing PX; Pietersz GA; Apostolopoulos V; Vaughan H; Karanikas V; Kyriakou P; McKenzie IF; Mitchell PL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):869-77. PubMed ID: 16467101
[TBL] [Abstract][Full Text] [Related]
6. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
[TBL] [Abstract][Full Text] [Related]
7. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
8. The role of circulating angiogenic factors in patients operated on for localized malignant melanoma.
Bolander A; Wagenius G; Larsson A; Brattström D; Ullenhag G; Hesselius P; Ekman S; Bergqvist M
Anticancer Res; 2007; 27(5A):3211-7. PubMed ID: 17970063
[TBL] [Abstract][Full Text] [Related]
9. Current approaches in dendritic cell generation and future implications for cancer immunotherapy.
Tuyaerts S; Aerts JL; Corthals J; Neyns B; Heirman C; Breckpot K; Thielemans K; Bonehill A
Cancer Immunol Immunother; 2007 Oct; 56(10):1513-37. PubMed ID: 17503040
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma.
Homma S; Matai K; Irie M; Ohno T; Kufe D; Toda G
J Gastroenterol; 2003; 38(10):989-94. PubMed ID: 14614608
[TBL] [Abstract][Full Text] [Related]
11. Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment.
Eriksson P; Brattström D; Hesselius P; Larsson A; Bergström S; Ekman S; Goike H; Wagenius G; Brodin O; Bergqvist M
Neoplasma; 2006; 53(4):285-90. PubMed ID: 16830054
[TBL] [Abstract][Full Text] [Related]
12. Possible mechanisms inducing glomerulations in interstitial cystitis: relationship between endoscopic findings and expression of angiogenic growth factors.
Tamaki M; Saito R; Ogawa O; Yoshimura N; Ueda T
J Urol; 2004 Sep; 172(3):945-8. PubMed ID: 15311005
[TBL] [Abstract][Full Text] [Related]
13. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)].
Nadar SK; Blann A; Beevers DG; Lip GY
J Intern Med; 2005 Oct; 258(4):336-43. PubMed ID: 16164572
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma.
Kamstock D; Elmslie R; Thamm D; Dow S
Cancer Immunol Immunother; 2007 Aug; 56(8):1299-309. PubMed ID: 17502972
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell immunotherapy for stage IV melanoma.
O'Rourke MG; Johnson MK; Lanagan CM; See JL; O'Connor LE; Slater GJ; Thomas D; Lopez JA; Martinez NR; Ellem KA; Schmidt CW
Melanoma Res; 2007 Oct; 17(5):316-22. PubMed ID: 17885587
[TBL] [Abstract][Full Text] [Related]
16. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
17. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma.
Papewalis C; Fassnacht M; Willenberg HS; Domberg J; Fenk R; Rohr UP; Schinner S; Bornstein SR; Scherbaum WA; Schott M
Clin Endocrinol (Oxf); 2006 Aug; 65(2):215-22. PubMed ID: 16886963
[TBL] [Abstract][Full Text] [Related]
19. Optimizing dendritic cell-based immunotherapy for cancer.
Zhong H; Shurin MR; Han B
Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
Bequet-Romero M; Ayala M; Acevedo BE; Rodríguez EG; Ocejo OL; Torrens I; Gavilondo JV
Angiogenesis; 2007; 10(1):23-34. PubMed ID: 17273909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
